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rare event in a BMD carrier. I also became aware of a condition of
autosomal recessive origin3 that fitted the clinical and CK findings
in the proband and his affected sister. Nevertheless, because BMD
was thought to be more common than ARMD, BMD remained a
signficant possibility. When RFLP technology became really
powerful, with the identification of flanking markers to the BMD
locus, I decided to apply it to this diagnostic problem. The findings
argued against BMD.
The table compares the probabilities of the RFLP findings, CK
readings, and pedigree pattern on the assumption that the sisters are
both carriers for BMD and on the assumption of the autosomal
recessive form. ARMD is 55 000 times more likely than BMD. The
most important single factor contributing to this difference is the
double recombination deduced (if BMD) in the affected younger
sister. There seems to be much geographical variation4-6 in the
prevalence of ARMD. In the north of England the BMD:ARMD
ratio is roughly 2:1, so the relative likelihood of ARMD falls to
’27 000 for this family from Hull/Grimsby.
I have not been able to confirm, or deny, the possibility that the
mother’s maternal uncle had a similar condition to the proband.
Nor was I able to obtain information as to whether the parents of
this uncle were blood relatives. I have therefore relied on the data
given in the table. A paternal relative had a neuromuscular disorder
designated Duchenne muscular dystrophy. The elder sister has had
a third son, normal on CK assay at six months of age, and I hope to
examine RFLP patterns in these three sons.
A diagnosis of BMD remains very unlikely. When RFLP
findings do not correspond to a putative diagnosis then that
diagnosis must be in doubt, and very much in doubt in this instance.
With respect to the points raised by Dr Cummings and Dr
Hodgson I can say that the paediatric neurologist’s clinical
examination and the histochemical and histological findings
strongly favour muscular dystrophy. I know of no form of X-linked
spinal muscular atrophy with the family pattern described above.
The findings in this family will be reported in detail elsewhere.
I thank Dr Andrew Read for discussing my approach to the data and Dr
Gwilym Hosking for his neurological opinion.
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GENE LOCATION IN TOURETTE SYNDROME
SIR,-Your editorial (Feb 7, p 308) reviewed the genetic aspects
of Tourette syndrome. The hypothesis that the syndrome is caused
by a highly penetrant dominant gene depends on the acceptance of
chronic tics or obsessive compulsive behaviour as part of the
syndrome. Comings et all have suggested that the gene responsible
is at 18q22’ 1. We have further evidence that this is the gene location.
A 23-year-old woman presented with a one-year history of mild
obsessive compulsive behaviour and a two-month history of more
severe behavioural problems. She repeatedly rearranged the
furniture, was restless, unable to remain seated, and constantly
plucked at her clothes. She had panic attacks and reported visual
hallucinations. Her early development was reported as slow
compared with her two normal elder brothers. Talipes of her left
foot had been treated by tendon transplant in childhood. She had
attended a normal primary and secondary school. Her nose was
small and her mid-face mildly hypoplastic. Cytogenetic analysis of
cultured lymphocytes revealed a deletion of the long arm of
chromosome 18 at 18q22-2. Her mother and two brothers have
normal karyotypes; examination of the father was not possible and
therefore the deletion may have been de novo or the result of a
paternal translocation.
This patient had the behavioural characteristics described in
members of Tourette families and a chromosome deletion at a
breakpoint very near one described in a family with Tourette
syndrome.! Thus the Tourette gene may be on the long arm of
chromosome 18.
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HLA-DR2 AND RAPID-EYE-MOVEMENT SLEEP
LATENCY: FAILURE TO REPLICATE
SIR,-We reported (Oct 4, p 803) that HLA-DR2 positive
normal subjects had shorter rapid-eye-movement (REM) sleep
latencies than HLA-DR2 negative subjects. This difference
suggested stronger inhibition of REM sleep release in HLA-DR2
negative subjects. No other sleep variable differed between the
groups. Because of the near perfect association between HLA-DR2
and narcolepsy,t,2 a disorder with notoriously short REM latency,
and the important theoretical implications of a link between the
HLA system and REM sleep, we repeated the study with a new
sample of normal subjects with the same protocol except that two
nights rather than one were spent in the sleep laboratory.
20 DR2 positive and 20 DR2 negative healthy subjects (age and
sex matched) entered this study. With the new sample, there were
no significant differences in any sleep variable that we had measured
before, including REM latency, between DR2 positive and DR2
negative subjects on either of the nights. The mean REM latency on
the first night was 111 ’2 min (SD 459) for the DR2 positive group
and 95-7 min (32-7) for the DR2 negative group. The values for the
second night were 100-4 min (45-4) and 87-0 min (39-8).
Since many variables (eg, laboratory environment, scoring
procedure, age) were similar, we conclude that the significant
difference in REM sleep latency in the first study appertained only
to that sample and that the fmdinly should not be seneralised.
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IN-UTERO EXPOSURE TO BENZODIAZEPINES
SiR,&mdash;The letter by Dr Laegreid and colleagues (Jan 10, p 108),
describing abnormalities in children exposed to benzodiazepines in
utero, contains a photograph and some case details of a 1-week-old
infant (case 2) who has the facial features of Zellweger syndrome.’
The brief clinical and pathological details provided-ie,
lissencephaly, distortion of neuronal migration, absence of the
caudal part of the cerebellum, Dandy-Walker malformation, and
polycystic kidneys-are all consistent with this diagnosis. Zellweger
syndrome is an autosomal recessive syndrome caused by a
deficiency of plasmalogens.2 Was this diagnosis excluded
biochemically in this infant? The abnormalities described may have
had nothing to do with benzodiazepines.
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